Total Payments
$406,273
2024 Payments
$160.81
Companies
9
Transactions
124
Medicare Patients
1,229
Medicare Billing
$187,775
Payment Breakdown by Category
Research$400,650 (98.6%)
Travel$4,258 (1.0%)
Food & Beverage$1,285 (0.3%)
Education$79.99 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $400,650 | 77 | 98.6% |
| Travel and Lodging | $4,258 | 16 | 1.0% |
| Food and Beverage | $1,285 | 30 | 0.3% |
| Education | $79.99 | 1 | 0.0% |
Payments by Type
Research
$400,650
77 transactions
General
$5,623
47 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| LEO Pharma AS | $260,138 | 9 | $0 (2018) |
| Glenmark Pharmaceuticals Inc. | $121,606 | 67 | $0 (2019) |
| Eli Lilly and Company | $18,906 | 1 | $0 (2018) |
| UCB Biosciences Inc. | $2,082 | 18 | $0 (2020) |
| PFIZER INC. | $1,948 | 5 | $0 (2023) |
| Celgene Corporation | $1,340 | 6 | $0 (2019) |
| ABBVIE INC. | $160.81 | 16 | $0 (2024) |
| Janssen Biotech, Inc. | $79.99 | 1 | $0 (2023) |
| VYNE Pharmaceuticals Inc. | $13.32 | 1 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $160.81 | 16 | ABBVIE INC. ($160.81) |
| 2023 | $2,028 | 6 | PFIZER INC. ($1,948) |
| 2020 | $2,095 | 19 | UCB Biosciences Inc. ($2,082) |
| 2019 | $117,745 | 31 | Glenmark Pharmaceuticals Inc. ($116,405) |
| 2018 | $177,936 | 50 | LEO Pharma AS ($153,830) |
| 2017 | $106,308 | 2 | LEO Pharma AS ($106,308) |
All Payment Transactions
124 individual payment records from CMS Open Payments — Page 1 of 5
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/09/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $7.95 | General |
| Category: IMMUNOLOGY | ||||||
| 11/25/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $7.02 | General |
| Category: IMMUNOLOGY | ||||||
| 11/11/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $5.97 | General |
| Category: IMMUNOLOGY | ||||||
| 11/04/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $7.95 | General |
| Category: IMMUNOLOGY | ||||||
| 10/14/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $13.69 | General |
| Category: IMMUNOLOGY | ||||||
| 09/23/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $7.25 | General |
| Category: IMMUNOLOGY | ||||||
| 08/26/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $7.25 | General |
| Category: IMMUNOLOGY | ||||||
| 08/12/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $10.47 | General |
| Category: IMMUNOLOGY | ||||||
| 07/15/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $15.04 | General |
| Category: IMMUNOLOGY | ||||||
| 07/08/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $11.50 | General |
| Category: IMMUNOLOGY | ||||||
| 06/17/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $15.88 | General |
| Category: IMMUNOLOGY | ||||||
| 05/20/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $6.03 | General |
| Category: IMMUNOLOGY | ||||||
| 05/13/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $12.88 | General |
| Category: IMMUNOLOGY | ||||||
| 03/18/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $7.90 | General |
| Category: IMMUNOLOGY | ||||||
| 03/04/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $12.89 | General |
| Category: IMMUNOLOGY | ||||||
| 02/19/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $11.14 | General |
| Category: IMMUNOLOGY | ||||||
| 10/30/2023 | Janssen Biotech, Inc. | TREMFYA (Drug) | Education | In-kind items and services | $79.99 | General |
| Category: Immunology | ||||||
| 08/28/2023 | PFIZER INC. | — | Travel and Lodging | In-kind items and services | $110.16 | General |
| 07/21/2023 | PFIZER INC. | — | Travel and Lodging | In-kind items and services | $951.00 | General |
| 07/21/2023 | PFIZER INC. | — | Food and Beverage | In-kind items and services | $404.02 | General |
| 07/21/2023 | PFIZER INC. | — | Travel and Lodging | In-kind items and services | $280.59 | General |
| 07/21/2023 | PFIZER INC. | — | Travel and Lodging | In-kind items and services | $202.03 | General |
| 04/02/2020 | UCB Biosciences Inc. | — | Travel and Lodging | Cash or cash equivalent | $69.00 | General |
| 04/02/2020 | UCB Biosciences Inc. | Bimekizumab | Travel and Lodging | Cash or cash equivalent | $69.00 | General |
| 04/02/2020 | UCB Biosciences Inc. | — | Food and Beverage | Cash or cash equivalent | $29.52 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| TRALOKINUMAB MONOTHERAPY FOR MODERATE TO SEVERE ATOPIC DERMATITIS - ECZTRA 2 ECZEMA TRALOKINUMAB TRIAL NO. 2 ECZTRA 2 | LEO Pharma AS | $260,138 | 9 |
| A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of GBR830 Administered to Adult Subjects with Moderate-to-Severe Atopic Dermatitis (AD) | Glenmark Pharmaceuticals Inc. | $116,405 | 25 |
| A MULTICENTER RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED STUDY COMPARING THE EFFICACY AND SAFETY OF LY2439821 TO ETANERCEPT AND PLACEBO IN PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS | Eli Lilly and Company | $18,906 | 1 |
| A Randomized Double Blind Placebo Controlled Parallel Group Dose Ranging Study Investigating the Efficacy Safety Pharmacokinetics and Pharmacodynamics of GBR830 Administered to Adult Subjects with Moderate to Severe Atopic Dermatitis AD | Glenmark Pharmaceuticals Inc. | $5,200 | 42 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 8 | 295 | 728 | $133,415 | $50,037 |
| 2022 | 8 | 295 | 637 | $115,132 | $47,088 |
| 2021 | 8 | 322 | 791 | $120,430 | $50,939 |
| 2020 | 8 | 317 | 698 | $102,590 | $39,711 |
Total Patients
1,229
Total Services
2,854
Medicare Billing
$187,775
Procedure Codes
32
All Medicare Procedures & Services
32 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 93 | 299 | $37,375 | $20,370 | 54.5% |
| 17111 | Destruction of skin growth, 15 or more growths | Office | 2023 | 55 | 149 | $59,600 | $15,811 | 26.5% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 64 | 64 | $12,800 | $4,935 | 38.6% |
| 17004 | Destruction of precancer skin growth, 15 or more growths | Office | 2023 | 13 | 26 | $10,400 | $3,507 | 33.7% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2023 | 22 | 25 | $4,500 | $2,177 | 48.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 16 | 21 | $3,255 | $1,797 | 55.2% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2023 | 17 | 29 | $2,610 | $897.57 | 34.4% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2023 | 15 | 115 | $2,875 | $542.52 | 18.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 101 | 307 | $38,307 | $21,128 | 55.2% |
| 17111 | Destruction of skin growth, 15 or more growths | Office | 2022 | 52 | 123 | $49,200 | $13,277 | 27.0% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 64 | 64 | $12,800 | $5,148 | 40.2% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2022 | 22 | 26 | $4,680 | $2,274 | 48.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 16 | 22 | $3,410 | $2,166 | 63.5% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 13 | 14 | $3,150 | $2,119 | 67.3% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2022 | 15 | 24 | $2,160 | $695.13 | 32.2% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2022 | 12 | 57 | $1,425 | $279.81 | 19.6% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 107 | 316 | $39,500 | $22,322 | 56.5% |
| 17111 | Destruction of 15 or more non-cancerous skin growths | Office | 2021 | 45 | 111 | $44,400 | $12,032 | 27.1% |
| 99203 | New patient outpatient visit, total time 30-44 minutes | Office | 2021 | 71 | 71 | $14,200 | $5,927 | 41.7% |
| 17110 | Destruction of up to 14 skin growths | Office | 2021 | 33 | 44 | $7,920 | $4,162 | 52.5% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 11 | 22 | $3,410 | $2,277 | 66.8% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 12 | 12 | $2,700 | $1,852 | 68.6% |
| 17000 | Destruction of skin growth | Office | 2021 | 24 | 45 | $4,050 | $1,518 | 37.5% |
| 17003 | Destruction of 2-14 skin growths | Office | 2021 | 19 | 170 | $4,250 | $850.79 | 20.0% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 99 | 253 | $31,625 | $14,195 | 44.9% |
About Dr. Lawrence Parish, MD
Dr. Lawrence Parish, MD is a Dermatology healthcare provider based in Philadelphia, Pennsylvania. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/19/2005. The National Provider Identifier (NPI) number assigned to this provider is 1548259815.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Lawrence Parish, MD has received a total of $406,273 in payments from pharmaceutical and medical device companies, with $160.81 received in 2024. These payments were reported across 124 transactions from 9 companies. The most common payment nature is "" ($400,650).
As a Medicare-enrolled provider, Parish has provided services to 1,229 Medicare beneficiaries, totaling 2,854 services with total Medicare billing of $187,775. Data is available for 4 years (2020–2023), covering 32 distinct procedure/service records.
Ad
Practice Information
- Specialty Dermatology
- Location Philadelphia, PA
- Active Since 10/19/2005
- Last Updated 07/31/2015
- Taxonomy Code 207N00000X
- Entity Type Individual
- NPI Number 1548259815
Products in Payments
- TALTZ (Drug) $18,906
- Otezla (Drug) $1,340
- Bimekizumab $1,041
- RINVOQ (Biological) $130.41
- TREMFYA (Drug) $79.99
- SKYRIZI (Biological) $30.40
- AMZEEQ (Drug) $13.32
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Dermatology Doctors in Philadelphia
Stephen Hess, Md, MD
Dermatology — Payments: $1.8M
Dermatology $1.8M
David Margolis, Md, MD
Dermatology — Payments: $1.1M
Dermatology $1.1M
Joel Gelfand, Md, MD
Dermatology — Payments: $787,044
Dermatology $787,044
Victoria Werth, Md, MD
Dermatology — Payments: $555,094
Dermatology $555,094
Dr. Harold Farber, M.d,, M.D,
Dermatology — Payments: $484,640
Dermatology $484,640
Dr. Jules Lipoff, Md, MD
Dermatology — Payments: $294,407
Dermatology $294,407